Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

09:34 EDT 31st July 2014 | BioPortfolio

Summary of "Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria."

Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an IgE monoclonal antibody that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients.

Affiliation

Department of Dermatology and Allergy, Charité-Universitätsmedizin, Berlin.

Journal Details

This article was published in the following journal.

Name: The New England journal of medicine
ISSN: 1533-4406
Pages: 924-35

Links

PubMed Articles [23727 Associated PubMed Articles listed on BioPortfolio]

Omalizumab in the Treatment of Chronic Urticaria.

Omalizumab is a monoclonal anti-immunoglobulin E antibody currently only approved for use in severe, refractory asthma. In recent years, many authors have reported satisfactory results with omalizumab...

Omalizumab, an anti-immunoglobulin E antibody: state of the art.

A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug a...

Biologic agents and the therapy of chronic spontaneous urticaria.

Chronic spontaneous urticaria (CSU) has been traditionally managed with antihistamines. Over the years, studies using different formulations and dosing regimens have delineated the limits of their eff...

Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust.

Omalizumab is a monoclonal antibody against IgE, nowadays approved for the treatment of persistent severe (EU) or moderate-to severe (USA) IgE-mediated asthma but there is also some evidence (case rep...

Up-dosing of non-sedating antihistamines in chronic urticaria: Need for well-designed clinical trials in India.

Urticaria is a heterogeneous group of diseases. Chronic urticaria significantly impacts quality-of-life of patients. Second generation, non-sedating antihistamines are recommended as first line treatm...

Clinical Trials [3440 Associated Clinical Trials listed on BioPortfolio]

Effect of Anti-IgE in Chronic Urticaria

This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in...

CUTE (Chronic Urticaria Treatment Evaluation)

A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity...

Etanercept for the Treatment of Chronic Urticaria

The purpose of this study is to evaluate the safety and efficacy of etanercept for patients with chronic idiopathic urticaria unresponsive to antihistamines.

A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)(COMPLETED)

This double-blind pilot study was conducted to establish the best way of using desloratadine treatment to protect quality of life of chronic idiopathic urticaria (CIU) patients, after an i...

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Ur...

Medical and Biotech [MESH] Definitions

A long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. The drug is well tolerated and has no anticholinergic side effects.

A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.

A spontaneous diminution or abatement of a disease over time, without formal treatment.

Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

Search BioPortfolio: